Osamu Muto

Osamu Muto

Auto-generated profile, based on publicly available information

Osamu Muto

Division of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
DMDaisuke Muraoka
Daisuke Muraoka
Meng Ling MoiMeng Ling Moi
Meng Ling Moi
OMOsamu Muto
Osamu Muto
TNTakaaki Nakatsukasa
Takaaki Nakatsukasa
SDSituo Deng
Situo Deng
NHNaozumi Harada
Naozumi Harada
Vaccine-induced T cells and neutralizing antibodies are essential for protection against SARS-CoV-2. Previously, we demonstrated that an antigen delivery system, pullulan nanogel (PNG), delivers vaccine antigen to lymph node medullary macrophages and thereby enhances the induction of specific CD8+ T cells. In this study, we revealed that medullary macrophage-selective delivery by PNG depends on its binding to a C-type lectin SIGN-R1. In a K18-hACE2 mouse model of SARS-CoV-2 infection, vaccination with a PNG-encapsulated receptor-binding domain of spike protein decreased the viral load and prolonged the survival in the CD8+ T cell- and B cell-dependent manners. T cell receptor repertoire analysis revealed that although the vaccine induced T cells at various frequencies, low-frequency specific T cells mainly promoted virus clearance. Thus, the induction of specific CD8+ T cells that respond quickly to viral infection, even at low frequencies, is important for vaccine efficacy and can be achieved by SIGN-R1+ medullary macrophage-targeted antigen delivery.